Navigation Links
'EuroVacc 02' HIV Vaccine Trial Begins

This press release isn't very clear, especially when it comes to the vaccine description; be sure to read the 'note' part at the end if you want to understand what the vaccine is about.

Lausanne, Switzerland and London, United Kingdom, February 16, 2005 -- The European Vaccine Effort against HIV/AIDS today announced that a phase I clinical trial of novel investigational vaccines comprising DNA-HIV-C and NYVAC-HIV-C for the prevention of HIV infection has started in Lausanne and London in February 2005. These vaccines are based on HIV subtype C, which is prevalent in China, India and sub-Saharan Africa, and constitutes more than 50 percent of the new HIV infections worldwide.

The phase I clinical trial, with the EuroVacc Foundation as the sponsor, will evaluate the safety of DNA-HIV-C alone and of the prime-boost regimen of DNA-HIV-C+NYVAC-HIV-C, and to compare the immunogenicity of the prime-boost regimen to NYVAC-HIV-C alone in healthy volunteers at low risk of acquiring HIV infection. The study will recruit 40 healthy volunteers: 20 at the Centre Hospitalier Universitaire Vaudois (CHUV) in Lausanne, and 20 at St Mary's Hospital, Imperial College London. All volunteers, male or female, should be between 18 and 55 yrs, HIV-negative and at low risk of infection.

The trial will carefully evaluate the safety and immunogenicity of the combination of the vaccines, in particular their ability to generate HIV-specific cell-mediated immune response to HIV, which is considered to be a key determinant of protection against infection. According to the principal clinical investigators Prof. Giuseppe Pantaleo of CHUV in Lausanne and Prof. Jonathan Weber of Imperial College London for the clinical studies, "if this study generates promising results, EuroVacc intends to further evaluate the vaccines in larger clinical trials."

Development background

The vaccine candidates for the trial - DNA-HIV-C and NYVAC-HIV-C - were develo
'"/>

Source:Imperial College London


Page: 1 2 3

Related biology news :

1. FDA Approves Human Hookworm Vaccine for Phase I Safety Trials
2. Live Recombinant Adenovirus Vaccine Technique Explored
3. Gene Vaccine Protects Mice Against Development Of Her2/neu Breast Cancer
4. NIAID Initiates Trial of Experimental Avian Flu Vaccine
5. Study Models Impact Of Anthrax Vaccine
6. New Insights Into HIV Immunity Suggest Alternative Approach to Vaccines
7. Pathogen-Mimicking Vaccine As Strategy For Cancer Therapy
8. Active Vaccine Prevents Mice From Developing Prion Disease
9. New Vaccine To Be Used For First Time In Polio Outbreak Response
10. Boosting The BCG Vaccine To Beat Tuberculosis
11. Visceral Leishmaniasis: Successful Vaccine Trial In Dogs
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: EuroVacc HIV Vaccine Trial Begins

(Date:3/23/2015)... , March 23, 2015   HOYOS Labs ... management company, today announced that the Company will demonstrate ... both enterprise and consumers at Connect:ID on March 23 ... HOYOS Labs will highlight the IEEE Biometric Open ... ; and enterprise access control system. BOPS was ...
(Date:3/23/2015)... , Mar. 23, 2015 NXT-ID, Inc. (NASDAQ: ... focused on the growing mobile commerce market, announces its biometric ... advertising campaign on CNBC television starting March 30 th ... commence airing in New York markets. ... said: "We are excited about our new ad campaign following ...
(Date:3/20/2015)... DUBLIN , Mar. 19, 2015 Research and Markets ... the "Hand Geometry - Global Strategic Business Report" ... worldwide markets for Hand Geometry in US$ Thousands. The report ... , Japan , Europe ... America , and Rest of World. Annual ...
Breaking Biology News(10 mins):HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 2HOYOS Labs to Showcase Host of Biometrics Technologies at Connect:ID in Washington, D.C. 3NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 2NXT-ID's Wocket Smart Wallet to Launch New CNBC Regional TV Ad Campaign 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4
... The Cultural Programs of the National Academy of Sciences ... with the Center for Art, Design, and Visual Culture ... Master of Arts in Museum Studies Program. The ... April 5 through April 14. A group of ...
... Grand Rapids, Mich. (April 1, 2010) ... two proteins required for the initiation and development of ... lead to improved treatments for the disease. One ... drug target for prostate cancer. The other, steroid ...
... S.C. As peach trees go, it doesn,t look much ... Research Farm, but appearances can be deceiving. This one, a ... a standout in the orchard. Its DNA its genetic ... scientists, enabling further research to identify beneficial traits to grow ...
Cached Biology News:NAS announces visual culture and evolution online symposium 2NAS announces visual culture and evolution online symposium 3VARI study could improve treatments for prostate cancer 2Researchers sequence DNA of peach tree at Clemson University 2Researchers sequence DNA of peach tree at Clemson University 3
(Date:3/30/2015)... 2015  NuGene International, Inc. ("NuGene") (OTCQB: NUGN), ... Inc. has added another internationally recognized researcher to ... an internationally recognized researcher in bio-inspired materials and ... Peking University, China , Professor ... of North Carolina, Chapel Hill. Following a postdoctoral ...
(Date:3/30/2015)... , March 30, 2015    Intrexon Corporation ... synthetic biology, and Merck Serono, the biopharmaceutical business ... , today announced an exclusive strategic collaboration and ... Receptor T-cell (CAR-T) cancer therapies. This collaboration advances ... therapies that modulate the immune system,s natural ability ...
(Date:3/30/2015)... Richmond Pharmacology nimmt weltweit ... ist das erste Zentrum weltweit, das in Zusammenarbeit ... in London in einer ... an einem Patienten begonnen hat. Das Therapeutikum wurde ... (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... 2015 As a symbol of its ... our pharmaceutical manufacturing clients, Whitehouse Laboratories is excited to ... Berkenstock Race Team for the 2015 race season. Success ... but a strong sense of precision and attention to ... success in the quality control testing laboratory. Sponsorship of ...
Breaking Biology Technology:UCI Professor Zhibin Guan Joins NuGene Advisory Board 2UCI Professor Zhibin Guan Joins NuGene Advisory Board 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2
... Wisconsin Entrepreneurs Conference, held at the Hyatt Regency Milwaukee, ... on starting a company, learn how to improve revenue ... state. , ,However, at the conference luncheon on Tuesday, ... industry representatives by the guest speakers: inspiration. During ...
... Wisconsins technology industry is often compared unfavorably to ... venture capital investments, more college graduates and a long ... part, our Minnesota envy is justified but not ... months, Minnesota biotech leaders have been quoted in Twin ...
... part of a three-part series focusing on the past, ... and initiatives, and serves as a follow up to ... , ,In this final installment, Nettles addresses outsourcing issues ... companies in regard to state bids, Wisconsins technology marketing ...
Cached Biology Technology:Celebrating Wisconsins entrepreneurial spirit 2Celebrating Wisconsins entrepreneurial spirit 3In biotech competition, Wisconsin isnt first but its far from last 2In biotech competition, Wisconsin isnt first but its far from last 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 3) 2WTN exclusive interview with Commerce Secretary Cory Nettles (part 3) 3WTN exclusive interview with Commerce Secretary Cory Nettles (part 3) 4WTN exclusive interview with Commerce Secretary Cory Nettles (part 3) 5
... This CLS number ... number, created to easily ... If showing no availability ... the old Sigma-Aldrich number ...
Request Info...
Designed for use with any of the Agencourt kits in tube format....
This device is designed to run four simultaneous separations with the following StemSep ; column sizes: 0.3in., 0.5in., and 0.6in.. Depending on the column size, a range of 2x10 7 - 1.5 x 10 9 cell...
Biology Products: